Globe Life (GL) just wrapped up FY 2025 with Q4 total revenue of US$1.5b and basic EPS of US$3.35, alongside net income of US$266.1m. On a trailing 12 month basis revenue came in at US$6.0b with EPS of US$14.27 and net income of US$1.2b. The company reported quarterly revenue of US$1.47b in Q4 2024 compared with US$1.5b in Q4 2025, while basic EPS increased from US$3.04 to US$3.35 over the same period, giving investors a snapshot of top line and earnings per share levels feeding into profit margins.

See our full analysis for Globe Life.

With the headline numbers on the table, the next step is to compare these results with the most widely held narratives about Globe Life to see which storylines are supported by the figures and which might be due for a rethink.

Margins Hold With 19.4% Net Profit

• On a trailing 12 month basis, Globe Life converted US$6.0b of revenue into US$1.2b of net income, which works out to a 19.4% net margin compared with 18.5% a year earlier.
• What stands out for bullish investors is that this margin profile sits alongside trailing EPS of US$14.27 and five year earnings growth of 8.7% per year. This combination supports the idea of a profit engine that has been resilient even as one year earnings growth of 8.4% comes in just under that longer term pace.
  • Bulls often point to consistent profitability and here the combination of US$1.2b of trailing net income and a 19.4% margin aligns with that view rather than contradicting it.
  • At the same time, the slight gap between the 8.4% one year earnings growth and the 8.7% five year trend gives bulls a data point to watch rather than a clear acceleration.

To see how these profitability trends fit into the long term story, many investors look at fuller narrative breakdowns like 📊 Read the full Globe Life Consensus Narrative. for extra context around earnings durability and risks.

Valuation Gap vs DCF Fair Value

• Globe Life is reported at a share price of US$146.95 compared with a DCF fair value estimate of about US$364.82, and a trailing P/E of 10.1x that sits below the US insurance industry average of 13x and the peer average of 10.7x.
• Consensus style, value oriented arguments often refer to this discount, and the figures do support that on paper. They also highlight that the stock is not being priced like a faster growth name when you set the 3.4% forecast earnings growth and 5.1% forecast revenue growth alongside higher US market forecasts of 15.7% and 10.3% respectively.
  • The combination of a roughly 59.7% gap to the DCF fair value and a P/E below both industry and peers is consistent with a value narrative, while the slower expected growth rates explain why some investors might still be cautious.
  • For anyone comparing across sectors, those growth figures help explain why the market may be assigning a lower multiple even with the historical earnings growth of 8.7% per year over five years.

Earnings Trend Across Recent Quarters

• Within FY 2025, quarterly EPS moved around, with US$3.05 in Q1, US$3.09 in Q2, US$4.81 in Q3 and US$3.35 in Q4, while revenue stayed in a tighter band between US$1.48b and US$1.52b across those same quarters.
• General market commentary around slower forecast growth is put into context by this pattern, because the steady revenue range and trailing 12 month revenue of US$6.0b alongside EPS of US$14.27 show a business that has produced stable top line and multi year earnings growth of 8.7% per year, even as forward looking expectations call for 3.4% earnings growth and 5.1% revenue growth per year.
  • Critics who focus on the lower forecast growth versus the broader US market may see the quarterly EPS swings as a reminder that single period strength, such as Q3 EPS of US$4.81, does not automatically translate into higher long term growth assumptions.
  • Supporters may instead point to the full year net income of about US$1.2b and the 19.4% net margin as evidence that the underlying franchise has held up, regardless of quarter to quarter moves.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Globe Life's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

See What Else Is Out There

Globe Life pairs solid margins with relatively modest forecast earnings and revenue growth compared with the broader US market, which may limit upside potential for some investors.

If that slower growth profile leaves you wanting more, you can quickly scan our 55 high quality undervalued stocks to hunt for companies where valuations and expected progress feel more compelling.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.